Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

ClinicalTrials.gov ID: NCT01773785

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01773785. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.

Study identification

NCT ID: NCT01773785
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Biliary Cancer

Interventions

SPI-1620 Drug
Docetaxel Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2013 (Actual)
Primary completion: Sep 2015 (Actual)
Completion: Sep 2015 (Actual)
Last update posted: Oct 13, 2021

2013 – 2015

United States locations

U.S. sites: 6
U.S. states: 4
U.S. cities: 6

Facility	City	State	ZIP	Site status
University of Miami Hospitals & Clinics/ Sylvester Comprehensive Cancer Center	Miami	Florida	33136	—
H. Lee Moffitt Cancer Center	Tampa	Florida	33612	—
Washington University School of Medicine	St Louis	Missouri	—	—
Associates in Oncology and Hematology	Chattanooga	Tennessee	37421	—
The West Clinic	Memphis	Tennessee	38120	—
Seattle Cancer Care Alliance	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01773785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2021 · Synced Nov 13, 2026